Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

被引：20

作者：

Buettner, Ralf ^{[1
]}

Morales, Corey ^{[1
]}

Caserta, Enrico ^{[1
]}

Troadec, Estelle ^{[1
]}

Gunes, Emine G. ^{[1
]}

Viola, Domenico ^{[1
]}

Khalife, Jihane ^{[1
]}

Li, Hongzhi ^{[2
]}

Keats, Jonathan J. ^{[3
]}

Christofferson, Austin ^{[3
]}

Wu, Xiwei ^{[4
]}

Synold, Timothy W. ^{[5
]}

Palmer, Joycelynne ^{[2
]}

Sanchez, James F. ^{[1
]}

Pozhitkov, Alexander ^{[2
]}

Vaidehi, Nagarajan ^{[2
]}

Marcucci, Guido ^{[6
]}

Krishnan, Amrita ^{[1
]}

Rosenzweig, Michael A. ^{[1
]}

Pichiorri, Flavia ^{[1
]}

Rosen, Steven T. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Hematol Malignancies & Stem Cell Transplantat Ins, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Computat & Quantitat Med, Duarte, CA USA

[3] Translat Genom Res Inst, Integrated Canc Genom, Phoenix, AZ USA

[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Integrat Genom Core, Duarte, CA USA

[5] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA

[6] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Gehr Family Ctr Leukemia Res, Hematol Malignancies & Stem Cell Transplantat Ins, Duarte, CA USA

来源：

BLOOD ADVANCES | 2019年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

MULTIPLE-MYELOMA; KINASE INHIBITOR; IDENTIFICATION; ACTIVATION; PROMOTES; DRUG;

D O I：

10.1182/bloodadvances.2018027227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1027 / 1032

页数：6

共 25 条

[1] The survival kinases Akt and Pim as potential pharmacological targets [J].

Amaravadi, R ;

Thompson, CB .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2618-2624

[2] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity [J].

Anastassiadis, Theonie ;

Deacon, Sean W. ;

Devarajan, Karthik ;

Ma, Haiching ;

Peterson, Jeffrey R. .

NATURE BIOTECHNOLOGY, 2011, 29 (11) :1039-U117

[3] Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach [J].

Baker, Angela ;

Braggio, Esteban ;

Jacobus, Susanna ;

Jung, Sungwon ;

Larson, Dirk ;

Therneau, Terry ;

Dispenzieri, Angela ;

Van Wier, Scott A. ;

Ahmann, Gregory ;

Levy, Joan ;

Perkins, Louise ;

Kim, Seungchan ;

Henderson, Kimberly ;

Vesole, David ;

Rajkumar, S. Vincent ;

Jelinek, Diane F. ;

Carpten, John ;

Fonseca, Rafael .

BLOOD, 2013, 121 (16) :3147-3152

[4] Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells [J].

Baumann, Philipp ;

Mandl-Weber, Sonja ;

Voelkl, Andreas ;

Adam, Christian ;

Bumeder, Irmgard ;

Oduncu, Fuat ;

Schmidmaier, Ralf .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) :366-375

[5] Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities [J].

Blanco-Aparicio, Carmen ;

Carnero, Amancio .

BIOCHEMICAL PHARMACOLOGY, 2013, 85 (05) :629-643

[6] Leflunomide: mode of action in the treatment of rheumatoid arthritis [J].

Breedveld, FC ;

Dayer, JM .

ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (11) :841-849

[7]

Buettner R, 2017, BLOOD, V130

[8] AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies [J].

Chesi, Marta ;

Robbiani, Davide F. ;

Sebag, Michael ;

Chng, Wee Joo ;

Affer, Maurizio ;

Tiedemann, Rodger ;

Valdez, Riccardo ;

Palmer, Stephen E. ;

Haas, Stephanie S. ;

Stewart, A. Keith ;

Fonseca, Rafael ;

Kremer, Richard ;

Cattoretti, Giorgio ;

Bergsagel, P. Leif .

CANCER CELL, 2008, 13 (02) :167-180

[9] Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma [J].

Chng, W-J ;

Huang, G. F. ;

Chung, T. H. ;

Ng, S. B. ;

Gonzalez-Paz, N. ;

Troska-Price, T. ;

Mulligan, G. ;

Chesi, M. ;

Bergsagel, P. L. ;

Fonseca, R. .

LEUKEMIA, 2011, 25 (06) :1026-1035

[10] The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase [J].

Davis, JP ;

Cain, GA ;

Pitts, WJ ;

Magolda, RL ;

Copeland, RA .

BIOCHEMISTRY, 1996, 35 (04) :1270-1273

← 1 2 3 →